New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
ProQR Therapeutics N.V.
PRQR
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

283M

Biotechnology

Next Earning date - 05 Nov 2024

283M

Biotechnology

Next Earning date - 05 Nov 2024

3.46USD
Shape0.01 ( 0.29%)
favorite-chart

Relative Strenght

29
favorite-chart

Volume Buzz

-63%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

25%

Quote Panel

Shape
Updated October 27, 2024
1W -14.57 % 1M 90.11 % 3M 91.16 % 1Y 188.33 %

Key Metrics

Shape
  • Market Cap

    282.61M


  • Shares Outstanding

    81.68M


  • Share in Float

    52.75M


  • Dividende

    0


  • Earning Date

    05 Nov 2024


  • Price Target

    3.46


  • Average Volume

    1.22M


  • Beta

    0.384


  • Range

    1.11-4.62


  • Industry

    Biotechnology


  • Website

    https://www.proqr.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

17.01x

P/S Ratio

7.96x

P/B Ratio

0.5

Debt/Equity

-139.5%

Net Margin

$-0.3

EPS

How PRQR compares to sector?

P/E Ratio

Relative Strength

Shape

PRQR

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$14M

Shape124%

2025-Revenue

$0.40

Shape-1122%

2025-EPS

$9M

Shape-178%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Chardan Capital

upgrade

Previous: Not converted

2023-11-08

Now: Buy

JMP Securities

upgrade

Previous: Market Perform

2023-03-30

Now: Market Outperform

Cantor Fitzgerald

upgrade

Previous: Not converted

2022-12-22

Now: Overweight

Raymond James

upgrade

Previous: Not converted

2022-08-11

Now: Outperform

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.34
vs -0.26

Q4.22

arrow
arrow

N/A

-0.16
vs -0.30

Q1.23

arrow
arrow

N/A

-0.12
vs -0.22

Q2.23

arrow
arrow

N/A

-0.11
vs -0.22

Q3.23

arrow
arrow

N/A

-0.08
vs -0.34

Q4.23

arrow
arrow

N/A

-0.08
vs -0.16

Q1.24

arrow
arrow

N/A

-0.10
vs -0.12

Q2.24

arrow
arrow

N/A

-0.03
vs -0.11

Q3.24

arrow
arrow

N/A

-0.11
vs -0.08

Q4.24

arrow
arrow

N/A

-0.09
vs -0.08

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+10%

956K  vs 872K

Q4.22

arrow
arrow

+244%

822K  vs 239K

Q1.23

arrow
arrow

-47%

655K  vs 1.2M

Q2.23

arrow
arrow

+18%

1.2M  vs 1M

Q3.23

arrow
arrow

+43%

1.4M  vs 956K

Q4.23

arrow
arrow

+289%

3.2M  vs 822K

Q1.24

arrow
arrow

+583%

4.5M  vs 655K

Q2.24

arrow
arrow

+426%

6.3M  vs 1.2M

Q3.24

arrow
arrow

+706%

11M  vs 1.4M

Q4.24

arrow
arrow

+26%

4M  vs 3.2M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-38%

-0.38
vs -0.17

Q4.22

arrow
arrow

-16%

-0.16
vs -0.38

Q1.23

arrow
arrow

-14%

-0.14
vs -0.16

Q2.23

arrow
arrow

-15%

-0.15
vs -0.14

Q3.23

arrow
arrow

-12%

-0.12
vs -0.15

Q4.23

arrow
arrow

-13%

-0.13
vs -0.12

Q1.24

arrow
arrow

-22%

-0.22
vs -0.13

Q2.24

arrow
arrow

-8%

-0.08
vs -0.22

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

47

47
vs 51

-8%

Q4.22

arrow
arrow

51

51
vs 47

9%

Q1.23

arrow
arrow

57

57
vs 51

12%

Q2.23

arrow
arrow

53

53
vs 57

-7%

Q3.23

arrow
arrow

45

45
vs 53

-15%

Q4.23

arrow
arrow

48

48
vs 45

7%

Q1.24

arrow
arrow

51

51
vs 48

6%

Q2.24

arrow
arrow

50

50
vs 51

-2%

Earnings Growth

Latest News